18 and older, any sex, with Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
The Difference in Data Collection Consistency Between Groups Across Three WeeksPrimary· Three-week trial period
Consistency was the percentage of intervals in which aides entered data per session with children during each school day, across a three week period. These metrics were captured via web analytics in partnership with our digital health company.
Group
Value
95% CI
Enhanced Electronic Platform
.66
.51 – .80
Electronic Platform Not Enhanced
.44
.19 – .70
The Difference in Data Collection Completion Between Groups Across Three WeeksPrimary· Three-week trial period
Consistency was the percentage of intervals in which aides entered data per session with children during each school day, across a three week period. These metrics were captured via web analytics in partnership with our digital health company.
Group
Value
95% CI
Enhanced Electronic Platform
.81
.67 – .96
Electronic Platform Not Enhanced
.98
.96 – 1.00
The Difference in Data Collection Timeliness Between Groups Across Three WeeksPrimary· Three-week trial period
Consistency was the percentage of intervals in which aides entered data per session with children during each school day, across a three week period. These metrics were captured via web analytics in partnership with our digital health company.
Group
Value
95% CI
Enhanced Electronic Platform
4.69
1.76 – 7.62
Electronic Platform Not Enhanced
71.87
-9.32 – 153.05
Intentions for ImplementorsSecondary· Assessed at baseline and end of 3-week trial period
We adapted scales to measure mechanisms affecting data collection, including intentions, using social psychology methods (Armitage \& Connor, 2001). The intentions measure had one item, which was rated from 1=strongly disagree to 7=strongly agree. Strongly agree meant stronger intentions to take data. Aides completed measures at baseline and post-trial (3 weeks). Data reported are changes over time.
Group
Value
95% CI
Enhanced Electronic Platform
5.31
± 2.59
Electronic Platform Not Enhanced
5.91
± 2.07
System Usability ScaleSecondary· Three-week trial period
We used the System Usability Scale (SUS; Brooke, 1996) to measure aides' reactions to various statements regarding the app's usability with 10 items that use a 5-point scale from (1) strongly disagree to (5) strongly agree. The SUS has high internal consistent reliability (Cronbach's alpha = .91) and demonstrated sensitivity to change (Lewis, 2018). We adapted the original questionnaire to replace "system" with "app" across all items. The SUS is calculated as a proportion score out of 100, with higher scores indicating higher usability (≥85 = Excellent; ≥71 = Good; ≥51 = Okay (Bangor et al.).
Group
Value
95% CI
Enhanced Electronic Platform
76.4
± 15.2
Electronic Platform Not Enhanced
67.7
± 21.5
Attitudes for ImplementorsSecondary· Assessed at baseline and end of 3-week trial period
We adapted scales to measure mechanisms affecting data collection, including attitudes, using social psychology methods (Armitage \& Connor, 2001). The attitudes measure had one item, which was rated from 1=good to 7=bad (meaning that taking data would be bad). Attitudes had 2 items. These items were averaged to create the scale score which could range from 1 to 7 for each measure. Aides completed measures at baseline and post-trial (3 weeks). Data reported are changes over time.
Group
Value
95% CI
Enhanced Electronic Platform
6.54
± 1.03
Electronic Platform Not Enhanced
6.68
± 0.73
Perceived Norms for ImplementorsSecondary· Assessed at baseline and end of 3-week trial period
We adapted scales to measure mechanisms affecting data collection, including perceived norms, using social psychology methods (Armitage \& Connor, 2001). The perceived norms measure had one item, which was rated from 1=strongly disagree to 7=strongly agree. Strongly agree meant stronger influence of norms on taking data. Aides completed measures at baseline and post-trial (3 weeks). Data reported are changes over time.
Group
Value
95% CI
Enhanced Electronic Platform
5.62
± 2.14
Electronic Platform Not Enhanced
6.18
± 1.83
Descriptive Norms for ImplementorsSecondary· Assessed at baseline and end of 3-week trial period
We adapted scales to measure mechanisms affecting data collection, including descriptive norms, using social psychology methods (Armitage \& Connor, 2001). The perceived norms measure had one item, which was rated from 1=strongly disagree to 7=strongly agree. Strongly agree meant stronger influence of norms on taking data. Aides completed measures at baseline and post-trial (3 weeks). Data reported are changes over time.
Group
Value
95% CI
Enhanced Electronic Platform
6.08
± 1.60
Electronic Platform Not Enhanced
6.27
± 1.27
Self-Efficacy for ImplementorsSecondary· Assessed at baseline and end of 3-week trial period
We adapted scales to measure mechanisms affecting data collection, including self-efficacy, using social psychology methods (Armitage \& Connor, 2001). The self-efficacy measure had one item, which was rated from 1=strongly disagree to 7=strongly agree. Strongly agree meant stronger self-efficacy about taking data. Self-Efficacy had 2 items. These items were averaged to create the scale score which could range from 1 to 7 for each measure. Aides completed measures at baseline and post-trial (3 weeks). Data reported are changes over time.
Group
Value
95% CI
Enhanced Electronic Platform
5.5
± 1.72
Electronic Platform Not Enhanced
4.91
± 2.50
Sponsor's own description
In partnership with a digital health software company, the University research team created two versions of a mobile application to help behavioral health technicians (BHT's) who work with students with autism collect data. The first version comprises a basic electronic platform for data collection. The second version has the same basic electronic platform for data collection, plus additional features designed to increase motivation to collect data and ease the burden of data collection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07042347 — Testing a Measurement Feedback App to Improve Data Quality, Supervision & Outcomes in Behavioral Health
· NA
· not yet recruiting
Other recruiting trials for Autism Spectrum Disorder
Currently open trials in the same condition.
NCT07324057 — The Effects of Preoperative Intranasal Administration of Dexmedetomidine and Esketamine on Negative Postoperative Behavi
· NA
· recruiting
NCT07493096 — Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disor
· recruiting
NCT07505290 — Efficacy of the Korean PEERS® for Preschoolers (PEERS®-PS-K) Social Skills Intervention: A Randomized Controlled Trial f
· NA
· active not recruiting
NCT07524192 — A Self-Instructional Online Program for Early Childhood and Elementary Teachers Supporting Autistic Children and Childre
· NA
· recruiting
NCT07432776 — Effect of an 8-Week Pickleball Program for Adults With Autism: A Feasibility Trial With a Delayed-Control Design
· EARLY_PHASE1
· recruiting
Other University of Pennsylvania trials
Trials by the same sponsor.
NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA
· EARLY_PHASE1
· not yet recruiting
NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD
· NA
· not yet recruiting
NCT07489430 — DaxibotulinumtoxinA for Blepharospasm
· Phase 2
· not yet recruiting
NCT07463131 — Negative Income Tax Trial
· NA
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
Last refreshed: 7 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05207956.